Covaxia

COVAXX was a biotechnology company established as a subsidiary of United Biomedical (UBI) to develop a synthetic peptide-based vaccine for COVID-19. The company utilized a proprietary platform to design UB-612, a multitope vaccine candidate intended to trigger both high-titer neutralizing antibodies and a robust T-cell response against the SARS-CoV-2 virus. In early 2021, COVAXX merged with United Neuroscience to form Vaxxinity, a clinical-stage company that continues to advance the peptide vaccine technology. The company's approach was distinguished by its focus on high scalability, stability at standard refrigeration temperatures, and precise targeting of conserved viral epitopes.